Reduced Preterm Delivery in Type 1 Diabetics Through Early Methyldopa Administration
Pregnant women with Type 1 diabetes and microalbuminuria face a higher risk of preterm delivery. Researchers have investigated the impact of early antihypertensive treatment with methyldopa on this risk. In a study published in Diabetic Medicine, investigators found that introducing early antihypertensive treatment with methyldopa resulted in a significant reduction in preterm delivery before gestational week 34. The study, conducted by L.R. Nielsen and colleagues, compared the outcomes of two cohorts: one from 1995-1999 and the other from 2000-2003.
Key Takeaways:
- The introduction of early antihypertensive treatment with methyldopa in pregnant women with Type 1 diabetes and microalbuminuria resulted in a significant reduction in preterm delivery before gestational week 34.
- The prevalence of preterm delivery before 37 weeks was reduced from 62% to 40% (p=0.15), and preterm delivery before 34 weeks was reduced from 23% to zero (p=0.02).
- Preeclampsia was reduced from 42% to 20% (p=0.11), and perinatal mortality occurred in 4% vs. 0%.
- Birth weight was 3124 (767) g vs. 3279 (663) g.
- The study's findings suggest that early antihypertensive treatment with methyldopa may be an effective way to reduce the risk of preterm delivery in pregnant women with Type 1 diabetes and microalbuminuria.
Statistics:
- 23% of women in the old cohort delivered preterm before 34 weeks (p=0.02).
- 62% of women in the old cohort delivered preterm before 37 weeks (p=0.15).
- Birth weight in the new cohort was 3279 (663) g.
- Perinatal mortality occurred in 4% of the old cohort vs. 0% of the new cohort.
Sources:
- Nielsen, L.R., et al. (2006). Reduced prevalence of early preterm delivery in women with Type 1 diabetes and microalbuminuria - possible effect of early antihypertensive treatment during pregnancy. Diabet Med, 23(4), 426-431.
- World Disease Weekly. (2006). Reduced Preterm Delivery in Type 1 Diabetics Through Early Methyldopa Administration. NewsRx.com.